Seagen reports fourth quarter and full year 2021 financial results

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) today reported financial results for the fourth quarter and year ended december 31, 2021. the company also highlighted adcetris® (brentuximab vedotin), padcev® (enfortumab vedotin-ejfv), tukysa® (tucatinib) and tivdak® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its robust oncology pipeline. “total revenues of $1.6 billion in 2021 were driven by strong net product sales and reflect gro
SGEN Ratings Summary
SGEN Quant Ranking